in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
ScinoPharm and Coland form alliance for oncological injectable products for China
9:41 AM MDT | May 14, 2013 | Deepti Ramesh
Active pharmaceutical ingredients (APIs) manufacturer ScinoPharm Taiwan (Shanhua, Taiwan) says that it has formed a strategic alliance with Coland Holdings (Shanghai) to develop a series of generic oncological drugs for mainland China. The cooperation utilizes ScinoPharm’s process R&D and production advantages in the field of highly potent oncological APIs and Coland’s well-established marketing capabilities in China to build an active presence within China’s rapidly growing anticancer drug market. Under the alliance, ScinoPharm will provide...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee